|
US6136311A
(en)
|
1996-05-06 |
2000-10-24 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of cancer
|
|
JP4836451B2
(ja)
|
2002-07-18 |
2011-12-14 |
メルス ベー ヴェー |
抗体混合物の組換え生産
|
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
|
AU2006232287B2
(en)
|
2005-03-31 |
2011-10-06 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for producing polypeptides by regulating polypeptide association
|
|
ATE509033T1
(de)
|
2006-03-20 |
2011-05-15 |
Univ California |
Manipulierte anti-prostatastammzellenantigen (psca)-antikörper für krebs-targeting
|
|
US9670269B2
(en)
|
2006-03-31 |
2017-06-06 |
Chugai Seiyaku Kabushiki Kaisha |
Methods of modifying antibodies for purification of bispecific antibodies
|
|
ES2568436T3
(es)
|
2006-03-31 |
2016-04-29 |
Chugai Seiyaku Kabushiki Kaisha |
Procedimiento para controlar la farmacocinética en sangre de anticuerpos
|
|
PL2066694T3
(pl)
|
2006-09-29 |
2016-04-29 |
Oncomed Pharm Inc |
Kompozycje i sposoby diagnozowania i leczenia nowotworu
|
|
ES2593484T3
(es)
|
2007-03-29 |
2016-12-09 |
Genmab A/S |
Anticuerpos biespecíficos y métodos de producción de los mismos
|
|
EP3424529A1
(en)
|
2007-07-02 |
2019-01-09 |
Oncomed Pharmaceuticals, Inc. |
Compositions and methods for treating and diagnosing cancer
|
|
WO2009032949A2
(en)
|
2007-09-04 |
2009-03-12 |
The Regents Of The University Of California |
High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
|
|
BRPI0817294A2
(pt)
|
2007-09-26 |
2015-03-17 |
Chugai Pharmaceutical Co Ltd |
Método de modificação do ponto isoelétrico de anticorpo via substituição de aminoácido em cdr.
|
|
CA2700410C
(en)
*
|
2007-10-03 |
2020-10-06 |
Cornell University |
Treatment of proliferative disorders using antibodies to psma
|
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
|
ES2712732T3
(es)
|
2009-02-17 |
2019-05-14 |
Cornell Res Foundation Inc |
Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico
|
|
DK2417156T3
(en)
|
2009-04-07 |
2015-03-02 |
Roche Glycart Ag |
Trivalent, bispecific antibodies
|
|
WO2010129304A2
(en)
|
2009-04-27 |
2010-11-11 |
Oncomed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
NZ701769A
(en)
|
2009-09-16 |
2016-06-24 |
Genentech Inc |
Coiled coil and/or tether containing protein complexes and uses thereof
|
|
UY32920A
(es)
*
|
2009-10-02 |
2011-04-29 |
Boehringer Ingelheim Int |
Moleculas de unión biespecíficas para la terapia anti-angiogénesis
|
|
EP2488204B1
(en)
|
2009-10-16 |
2016-04-06 |
Oncomed Pharmaceuticals, Inc. |
Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
|
|
EP3135302A1
(en)
|
2009-12-02 |
2017-03-01 |
Imaginab, Inc. |
J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
|
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
|
EP4477668A3
(en)
|
2010-04-20 |
2025-03-19 |
Genmab A/S |
Heterodimeric antibody fc-containing proteins and methods for production thereof
|
|
CN102946906B
(zh)
|
2010-04-23 |
2015-07-15 |
弗·哈夫曼-拉罗切有限公司 |
生产异源多聚体蛋白质
|
|
PH12012502193A1
(en)
|
2010-05-06 |
2021-08-09 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
|
|
PE20130207A1
(es)
|
2010-05-06 |
2013-02-28 |
Novartis Ag |
Anticuerpos antagonistas de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6) y composiciones
|
|
US8551479B2
(en)
|
2010-09-10 |
2013-10-08 |
Oncomed Pharmaceuticals, Inc. |
Methods for treating melanoma
|
|
KR101398363B1
(ko)
|
2010-11-17 |
2014-05-22 |
추가이 세이야쿠 가부시키가이샤 |
혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
|
|
PL2647707T3
(pl)
|
2010-11-30 |
2019-02-28 |
Chugai Seiyaku Kabushiki Kaisha |
Środek terapeutyczny wywołujący cytotoksyczność
|
|
AR085091A1
(es)
|
2011-01-26 |
2013-09-11 |
Kolltan Pharmaceuticals Inc |
Anticuerpos anti-kit y sus usos
|
|
US10689447B2
(en)
*
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
|
CN103403025B
(zh)
|
2011-02-28 |
2016-10-12 |
弗·哈夫曼-拉罗切有限公司 |
单价抗原结合蛋白
|
|
RU2607038C2
(ru)
|
2011-02-28 |
2017-01-10 |
Ф. Хоффманн-Ля Рош Аг |
Антигенсвязывающие белки
|
|
US9527925B2
(en)
|
2011-04-01 |
2016-12-27 |
Boehringer Ingelheim International Gmbh |
Bispecific binding molecules binding to VEGF and ANG2
|
|
EP3144320B9
(en)
|
2011-04-13 |
2018-08-22 |
Bristol-Myers Squibb Company |
Fc fusion proteins comprising novel linkers or arrangements
|
|
AU2012245260B2
(en)
|
2011-04-22 |
2016-09-08 |
Aptevo Research And Development Llc |
Prostate-specific membrane antigen binding proteins and related compositions and methods
|
|
WO2012163521A1
(en)
*
|
2011-05-27 |
2012-12-06 |
Dutalys |
Removal of monomeric targets
|
|
EP3281640A1
(en)
|
2011-06-17 |
2018-02-14 |
President and Fellows of Harvard College |
Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer
|
|
UA117901C2
(uk)
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
|
|
EP2543680A1
(en)
*
|
2011-07-07 |
2013-01-09 |
Centre National de la Recherche Scientifique |
Multispecific mutated antibody Fab fragments
|
|
RU2014101669A
(ru)
|
2011-07-15 |
2015-09-20 |
Онкомед Фармасьютикалс, Инк. |
Агенты, связывающие белки r-спондины (rspo), и способы их применения
|
|
WO2013026839A1
(en)
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
|
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
|
AU2015268749B2
(en)
*
|
2011-09-23 |
2017-05-25 |
Oncomed Pharmaceuticals, Inc. |
VEGF/DLL4 binding agents and uses thereof
|
|
EA029958B1
(ru)
|
2011-09-23 |
2018-06-29 |
Онкомед Фармасьютикалс, Инк. |
Антитела, связывающие фактор роста эндотелия сосудов (vegf)/дельта-подобный лиганд (dll4), и их применение
|
|
WO2013060867A2
(en)
|
2011-10-27 |
2013-05-02 |
Genmab A/S |
Production of heterodimeric proteins
|
|
US11851476B2
(en)
|
2011-10-31 |
2023-12-26 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
|
|
BR112014010409A2
(pt)
|
2011-11-04 |
2017-04-25 |
Novartis Ag |
construtos que prolongam a meia-vida de proteína 6 (lrp6) relacionada à lipoproteína de baixa densidade
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
KR20140095096A
(ko)
|
2011-11-21 |
2014-07-31 |
제넨테크, 인크. |
항-c-met 항체의 정제
|
|
AU2012340766B2
(en)
|
2011-11-23 |
2018-05-10 |
Medimmune, Llc |
Binding molecules specific for HER3 and uses thereof
|
|
CA2861031C
(en)
|
2012-02-03 |
2022-10-25 |
Carole BOURQUIN |
Bispecific antibody molecules with antigen-transfected t-cells and their use in medicine
|
|
CA2868404A1
(en)
|
2012-04-05 |
2013-10-10 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies against human tweak and human il17 and uses thereof
|
|
KR20200126007A
(ko)
|
2012-04-20 |
2020-11-05 |
메뤼스 엔.페. |
Ig-유사 분자의 제조방법 및 제조수단
|
|
US9090694B2
(en)
|
2012-04-30 |
2015-07-28 |
Janssen Biotech, Inc. |
ST2L antibody antagonists
|
|
MX2014014951A
(es)
|
2012-06-06 |
2015-03-13 |
Oncomed Pharm Inc |
Agentes aglutinantes que modulan la trayectoria hippo y sus usos.
|
|
EP3632462A1
(en)
|
2012-07-06 |
2020-04-08 |
Genmab B.V. |
Dimeric protein with triple mutations
|
|
EP2869845B1
(en)
|
2012-07-06 |
2019-08-28 |
Genmab B.V. |
Dimeric protein with triple mutations
|
|
KR20150036603A
(ko)
|
2012-07-13 |
2015-04-07 |
온코메드 파마슈티칼스, 인크. |
Rspo3 결합제 및 그의 용도
|
|
NZ630363A
(en)
|
2012-07-25 |
2018-09-28 |
Celldex Therapeutics Inc |
Anti-kit antibodies and uses thereof
|
|
MY181648A
(en)
|
2012-08-24 |
2020-12-30 |
Univ California |
Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
|
|
KR102390177B1
(ko)
|
2012-09-27 |
2022-04-26 |
메뤼스 엔.페. |
T 세포 인게이저로서 이중특이적 IgG 항체
|
|
BR112015007120A2
(pt)
|
2012-10-08 |
2017-12-12 |
Roche Glycart Ag |
anticorpo biespecífico, composição farmacêutica, uso, célula hospedeira e método de produção de um anticorpo
|
|
US20150368329A1
(en)
*
|
2012-10-15 |
2015-12-24 |
Oncomed Pharmaceuticals, Inc. |
Methods of Treating Ocular Diseases
|
|
WO2014071018A1
(en)
|
2012-10-31 |
2014-05-08 |
Oncomed Pharmaceuticals, Inc. |
Methods and monitoring of treatment with a dll4 antagonist
|
|
EP2727943A1
(en)
|
2012-11-05 |
2014-05-07 |
MAB Discovery GmbH |
Trispecific antibodies against human EGFR, HER2 and HER3
|
|
WO2014067642A1
(en)
|
2012-11-05 |
2014-05-08 |
Mab Discovery Gmbh |
Method for the production of multispecific antibodies
|
|
EP2727942A1
(en)
|
2012-11-05 |
2014-05-07 |
MAB Discovery GmbH |
Bispecific antibodies against human EGFR, HER2, and HER3
|
|
EP2727941A1
(en)
|
2012-11-05 |
2014-05-07 |
MAB Discovery GmbH |
Method for the production of multispecific antibodies
|
|
CN104903351A
(zh)
|
2012-11-07 |
2015-09-09 |
辉瑞公司 |
抗-notch3抗体及抗体-药物缀合物
|
|
US20170275367A1
(en)
|
2012-11-21 |
2017-09-28 |
Janssen Biotech, Inc. |
Bispecific EGFR/C-Met Antibodies
|
|
ES2700231T3
(es)
|
2012-11-21 |
2019-02-14 |
Janssen Biotech Inc |
Anticuerpos de EGFR/c-Met biespecíficos
|
|
KR101569083B1
(ko)
|
2012-11-21 |
2015-11-16 |
주식회사 파멥신 |
Vegfr-2와 dll4를 표적으로 하는 이중표적항체 및 이를 포함하는 약학적 조성물
|
|
KR102264570B1
(ko)
|
2012-11-28 |
2021-06-14 |
자임워크스 인코포레이티드 |
가공된 면역글로불린 중쇄-경쇄 쌍 및 이들의 용도
|
|
US9914785B2
(en)
|
2012-11-28 |
2018-03-13 |
Zymeworks Inc. |
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
|
|
NZ709059A
(en)
|
2012-12-04 |
2016-11-25 |
Oncomed Pharm Inc |
Immunotherapy with binding agents
|
|
JP6377635B2
(ja)
|
2013-01-10 |
2018-08-22 |
ゲンマブ ビー．ブイ． |
ヒトＩｇＧ１Ｆｃ領域変異体およびその使用
|
|
WO2014124326A1
(en)
*
|
2013-02-08 |
2014-08-14 |
Stem Centrx, Inc. |
Novel multispecific constructs
|
|
ES2813501T3
(es)
|
2013-02-12 |
2021-03-24 |
Bristol Myers Squibb Co |
Métodos de replegado de proteínas basados en filtración de flujo tangencial
|
|
EP2956467B1
(en)
|
2013-02-12 |
2017-09-27 |
Bristol-Myers Squibb Company |
High ph protein refolding methods
|
|
PT2961771T
(pt)
|
2013-02-26 |
2020-02-28 |
Roche Glycart Ag |
Moléculas de ligação ao antigénio biespecíficas para ativação das células t, específicas para cd3 e cea
|
|
CN105143270B
(zh)
|
2013-02-26 |
2019-11-12 |
罗切格利卡特公司 |
双特异性t细胞活化抗原结合分子
|
|
WO2014141064A1
(en)
|
2013-03-13 |
2014-09-18 |
Novartis Ag |
Notch2 binding molecules for treating respiratory diseases
|
|
RU2015131718A
(ru)
*
|
2013-03-14 |
2017-04-19 |
Онкомед Фармасьютикалс, Инк. |
Мет-связывающие агенты и их применения
|
|
US9168300B2
(en)
|
2013-03-14 |
2015-10-27 |
Oncomed Pharmaceuticals, Inc. |
MET-binding agents and uses thereof
|
|
AR095374A1
(es)
|
2013-03-15 |
2015-10-14 |
Amgen Res Munich Gmbh |
Moléculas de unión para bcma y cd3
|
|
WO2014151422A1
(en)
|
2013-03-15 |
2014-09-25 |
Janssen Biotech, Inc. |
Interferon alpha and omega antibody antagonists
|
|
KR20160006168A
(ko)
|
2013-03-18 |
2016-01-18 |
바이오서오엑스 프로덕스 비.브이. |
인간화 항-cd134(ox40) 항체 및 이의 용도
|
|
SG10201810481UA
(en)
|
2013-04-29 |
2018-12-28 |
Hoffmann La Roche |
Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases
|
|
US20160068613A1
(en)
|
2013-04-29 |
2016-03-10 |
Hoffmann-La Roche Inc. |
Fc-receptor binding modified asymmetric antibodies and methods of use
|
|
PL2992012T3
(pl)
|
2013-04-29 |
2019-12-31 |
F. Hoffmann-La Roche Ag |
Zmodyfikowane ludzkie przeciwciała wiążące FcRn i sposoby ich zastosowania
|
|
ES2776706T3
(es)
|
2013-07-05 |
2020-07-31 |
Genmab As |
Anticuerpos contra CD3 humanizados o quiméricos
|
|
AU2014287984B2
(en)
*
|
2013-07-09 |
2016-09-22 |
Ablbio |
Novel dual-targeted protein specifically binding to DLL4 and VEGF, and use thereof
|
|
US11305012B2
(en)
|
2013-09-24 |
2022-04-19 |
Medimmune, Llc |
Binding molecules specific for HER3 and uses thereof
|
|
AU2014325063B2
(en)
|
2013-09-27 |
2019-10-31 |
Chugai Seiyaku Kabushiki Kaisha |
Method for producing polypeptide heteromultimer
|
|
RU2016115866A
(ru)
*
|
2013-10-11 |
2017-11-16 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифические антитела с обменянными доменами и одинаковыми вариабельными доменами легкой цепи
|
|
DK3065774T3
(da)
|
2013-11-06 |
2021-08-23 |
Janssen Biotech Inc |
Anti-CCL17-antistoffer
|
|
EP3736292B1
(en)
|
2013-12-17 |
2024-05-08 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
|
HRP20200384T1
(hr)
|
2013-12-20 |
2020-06-12 |
F. Hoffmann - La Roche Ag |
Humanizirana anti-tau(ps422) protutijela i načini uporabe
|
|
RU2693438C2
(ru)
|
2014-01-03 |
2019-07-02 |
Ф. Хоффманн-Ля Рош Аг |
Биспецифичные антитела против гаптена/против рецептора гематоэнцефалического барьера, их комплексы и их применение в качестве челноков гематоэнцефалического барьера
|
|
KR102381685B1
(ko)
|
2014-01-06 |
2022-04-01 |
에프. 호프만-라 로슈 아게 |
1가 혈액 뇌 장벽 셔틀 모듈
|
|
EP3094647A1
(en)
|
2014-01-15 |
2016-11-23 |
F. Hoffmann-La Roche AG |
Fc-region variants with modified fcrn- and maintained protein a-binding properties
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
CN106459212B
(zh)
|
2014-02-28 |
2021-07-13 |
美勒斯公司 |
结合erbb-2和erbb-3的抗体
|
|
US9732154B2
(en)
|
2014-02-28 |
2017-08-15 |
Janssen Biotech, Inc. |
Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
|
|
SG11201607109QA
(en)
|
2014-02-28 |
2016-09-29 |
Merus Nv |
Antibodies that bind egfr and erbb3
|
|
US20150259420A1
(en)
|
2014-03-14 |
2015-09-17 |
Novartis Ag |
Antibody molecules to lag-3 and uses thereof
|
|
ES2939760T3
(es)
|
2014-03-15 |
2023-04-26 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico para antígenos
|
|
EP3126389B1
(en)
|
2014-04-02 |
2024-10-23 |
F. Hoffmann-La Roche AG |
Method for detecting multispecific antibody light chain mispairing
|
|
UA117289C2
(uk)
|
2014-04-02 |
2018-07-10 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифічне антитіло
|
|
ES2896404T3
(es)
|
2014-04-04 |
2022-02-24 |
Crown Bioscience Inc Taicang |
Métodos para determinar la capacidad de respuesta a inhibidores de MEK/ERK
|
|
US11485790B2
(en)
|
2014-04-07 |
2022-11-01 |
Chugai Seiyaku Kabushiki Kaisha |
Immunoactivating antigen-binding molecule
|
|
US10745490B2
(en)
|
2014-04-11 |
2020-08-18 |
Celldex Therapeutics, Inc. |
Anti-ErbB antibodies and methods of use thereof
|
|
PL3140392T3
(pl)
|
2014-05-06 |
2023-11-27 |
F. Hoffmann-La Roche Ag |
Produkcja białek heteromultimerycznych z wykorzystaniem komórek ssaków
|
|
WO2015174439A1
(ja)
|
2014-05-13 |
2015-11-19 |
中外製薬株式会社 |
免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子
|
|
WO2015179737A2
(en)
|
2014-05-23 |
2015-11-26 |
Kolltan Pharmaceuticals, Inc. |
Treatment of eosinophil or mast cell related disorders
|
|
BR112016027888A2
(pt)
|
2014-05-28 |
2017-10-24 |
Zymeworks Inc |
construto de polipeptídeo de ligação ao antígeno isolado, polinucleotídeo isolado ou um conjunto de polinucleotídeos isolados, vetor ou conjunto de vetores, célula isolada, composição farmacêutica, uso do construto, método para tratar um sujeito com uma doença ou distúrbio, método para obter um construto, método para preparar um construto, meio de armazenamento legível por computador, método para produzir um construto de polipeptídeo de ligação com antígeno bi-específico e método para preparar um construto de polipeptídeo de ligação com antígeno isolado
|
|
TWI713453B
(zh)
|
2014-06-23 |
2020-12-21 |
美商健生生物科技公司 |
干擾素α及ω抗體拮抗劑
|
|
WO2015197736A1
(en)
|
2014-06-26 |
2015-12-30 |
F. Hoffmann-La Roche Ag |
Anti-brdu antibodies and methods of use
|
|
AR100978A1
(es)
|
2014-06-26 |
2016-11-16 |
Hoffmann La Roche |
LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
|
|
CA2952758A1
(en)
|
2014-07-11 |
2016-01-14 |
Genmab A/S |
Antibodies binding axl
|
|
US9777061B2
(en)
|
2014-07-21 |
2017-10-03 |
Novartis Ag |
Treatment of cancer using a CD33 chimeric antigen receptor
|
|
WO2016014530A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
|
KR102612313B1
(ko)
|
2014-07-21 |
2023-12-12 |
노파르티스 아게 |
인간화 항-bcma 키메라 항원 수용체를 사용한 암의 치료
|
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
EP3174546B1
(en)
|
2014-07-31 |
2019-10-30 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing t-cells
|
|
EP2982692A1
(en)
|
2014-08-04 |
2016-02-10 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
FI3608337T3
(fi)
|
2014-08-04 |
2024-06-13 |
Hoffmann La Roche |
Bispesifisiä t-solua aktivoivia antigeenia sitovia molekyylejä
|
|
JP6919118B2
(ja)
|
2014-08-14 |
2021-08-18 |
ノバルティス アーゲー |
ＧＦＲα−４キメラ抗原受容体を用いる癌の治療
|
|
PL3183268T3
(pl)
|
2014-08-19 |
2020-09-07 |
Novartis Ag |
Chimeryczny receptor antygenowy (CAR) anty-CD123 do zastosowania w leczeniu nowotworu złośliwego
|
|
RS60305B1
(sr)
|
2014-09-05 |
2020-07-31 |
Janssen Pharmaceutica Nv |
Agensi koji vezuju cd123 i njihove upotrebe
|
|
MX386886B
(es)
|
2014-09-09 |
2025-03-12 |
Janssen Biotech Inc |
Combinación de anticuerpos anti-cd38 y ácido todo-trans retinoico para usarse en terapias.
|
|
WO2016040895A1
(en)
|
2014-09-12 |
2016-03-17 |
xxTHE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY |
Wnt signaling agonist molecules
|
|
TW201628648A
(zh)
|
2014-09-16 |
2016-08-16 |
安可美德藥物股份有限公司 |
纖維變性疾病之治療
|
|
WO2016044605A1
(en)
|
2014-09-17 |
2016-03-24 |
Beatty, Gregory |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
|
WO2016055592A1
(en)
|
2014-10-09 |
2016-04-14 |
Engmab Ag |
Bispecific antibodies against cd3epsilon and ror1
|
|
ES2952717T3
(es)
|
2014-10-14 |
2023-11-03 |
Novartis Ag |
Moléculas de anticuerpos contra PD-L1 y usos de las mismas
|
|
DK3212233T3
(da)
|
2014-10-31 |
2020-07-27 |
Oncomed Pharm Inc |
Kombinationsterapi til behandling af sygdom
|
|
MX2017005150A
(es)
|
2014-11-06 |
2017-08-08 |
Hoffmann La Roche |
Variantes de region fc con propiedades modificadas de union a receptor neonatal fc (fcrn) y proteina a.
|
|
RU2714116C2
(ru)
|
2014-11-06 |
2020-02-11 |
Ф. Хоффманн-Ля Рош Аг |
ВАРИАНТЫ Fc-ОБЛАСТИ С МОДИФИЦИРОВАННЫМ СВЯЗЫВАНИЕМ FcRn И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
|
EP3023437A1
(en)
|
2014-11-20 |
2016-05-25 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
MX387463B
(es)
|
2014-11-20 |
2025-03-18 |
Hoffmann La Roche |
Moléculas de unión a antígeno biespecíficas activadoras de células t y antagonistas de unión al eje de pd-1 y usos de los mismos para el tratamiento de cáncer.
|
|
CN107074955B
(zh)
|
2014-11-20 |
2021-06-22 |
豪夫迈·罗氏有限公司 |
针对FolR1和CD3的T细胞活化性双特异性抗原结合分子
|
|
RS60615B1
(sr)
|
2014-11-20 |
2020-08-31 |
Hoffmann La Roche |
Zajednički laki lanci i postupci upotrebe
|
|
JP6721590B2
(ja)
|
2014-12-03 |
2020-07-15 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
多重特異性抗体
|
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
|
AU2015358615B2
(en)
|
2014-12-04 |
2021-08-05 |
Janssen Biotech, Inc. |
Anti-CD38 antibodies for treatment of acute myeloid leukemia
|
|
EP3233907B1
(en)
|
2014-12-19 |
2021-03-03 |
Genmab A/S |
Rodent bispecific heterodimeric proteins
|
|
CN114478792A
(zh)
|
2015-01-08 |
2022-05-13 |
根马布股份公司 |
针对cd3和cd20的双特异性抗体
|
|
WO2016159213A1
(ja)
|
2015-04-01 |
2016-10-06 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
|
CN119925616A
(zh)
|
2015-04-08 |
2025-05-06 |
诺华股份有限公司 |
Cd20疗法、cd22疗法和与cd19嵌合抗原受体（car）表达细胞的联合疗法
|
|
US12128069B2
(en)
|
2015-04-23 |
2024-10-29 |
The Trustees Of The University Of Pennsylvania |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
JP7103751B6
(ja)
*
|
2015-04-28 |
2022-08-15 |
ザイムワークス，インコーポレイテッド |
修飾された抗原結合ポリペプチド構築物及びその使用
|
|
EP3291836A4
(en)
|
2015-05-06 |
2018-11-14 |
Janssen Biotech, Inc. |
Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof
|
|
HK1253242A1
(zh)
|
2015-05-20 |
2019-06-14 |
Janssen Biotech, Inc. |
用於治疗轻链淀粉样变性及其它cd38阳性血液恶性肿瘤的抗cd38抗体
|
|
PL3310814T3
(pl)
|
2015-06-16 |
2023-12-11 |
F. Hoffmann-La Roche Ag |
Humanizowane i wykazujące dojrzałe powinowactwo przeciwciała przeciwko FcRH5 i sposoby stosowania
|
|
US10668149B2
(en)
|
2015-06-22 |
2020-06-02 |
Janssen Biotech, Inc. |
Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors
|
|
CA2990620A1
(en)
|
2015-06-24 |
2016-12-29 |
Janssen Biotech, Inc. |
Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38
|
|
JP6619460B2
(ja)
|
2015-06-24 |
2019-12-11 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
ヒト化抗タウ（ｐＳ４２２）抗体及び使用法
|
|
SMT202000359T1
(it)
|
2015-07-10 |
2020-09-10 |
Genmab As |
Coniugati anticorpo-farmaco specifici per axl per il trattamento del cancro
|
|
SI3115376T1
(sl)
|
2015-07-10 |
2018-12-31 |
Merus N.V. |
Humana protitelesa, ki vežejo CD3
|
|
BR112018000696A2
(pt)
|
2015-07-15 |
2018-09-18 |
Genmab As |
?anticorpo, métodos para reduzir e para aumentar a afinidade de ligação de um anticorpo que se liga ao cd3 humano, para tratar e para diagnosticar uma doença, para produzir um anticorpo e para detectar a presença de antígeno de cd3, construto de ácido nucleico, vetor de expressão, célula hospedeira, composição, e, kit?
|
|
JP6878405B2
(ja)
|
2015-07-29 |
2021-05-26 |
ノバルティス アーゲー |
Ｐｄ−１に対する抗体分子を含む組み合わせ治療
|
|
EP3878465A1
(en)
|
2015-07-29 |
2021-09-15 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
|
PT3317301T
(pt)
|
2015-07-29 |
2021-07-09 |
Novartis Ag |
Terapias de associação compreendendo moléculas de anticorpo contra lag-3
|
|
KR20180030917A
(ko)
|
2015-08-05 |
2018-03-26 |
얀센 바이오테크 인코포레이티드 |
항-cd154 항체 및 그의 사용 방법
|
|
CN108136012B
(zh)
|
2015-08-07 |
2022-10-04 |
伊麦吉纳博公司 |
靶向分子的抗原结合构建体
|
|
UA127515C2
(uk)
|
2015-08-17 |
2023-09-20 |
Янссен Байотек, Інк. |
Антитіло до всма, біспецифічна антигензв'язувальна молекула, що зв'язує всма і cd3, і їх використання
|
|
BR112017026543A2
(pt)
|
2015-08-26 |
2018-08-14 |
Bison Therapeutics Inc |
plataforma de anticorpo multiespecífico e métodos relacionados
|
|
JP6951825B2
(ja)
|
2015-09-04 |
2021-10-20 |
ザ スクリプス リサーチ インスティテュート |
インスリン免疫グロブリン融合タンパク質
|
|
UA126278C2
(uk)
|
2015-09-21 |
2022-09-14 |
Аптево Рісьорч Енд Девелопмент Ллс |
Поліпептиди, які зв'язують cd3
|
|
US11339213B2
(en)
|
2015-09-23 |
2022-05-24 |
Mereo Biopharma 5, Inc. |
Methods and compositions for treatment of cancer
|
|
CR20180177A
(es)
|
2015-09-30 |
2018-06-22 |
Janssen Biotech Inc |
Anticuerpos agonistas que se unen específicamente a cd40 humana y método de uso
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
IL257110B
(en)
|
2015-10-02 |
2022-09-01 |
Hoffmann La Roche |
Bispecific antibodies specific against pd1 and tim3
|
|
HK1254967A1
(zh)
|
2015-10-02 |
2019-08-02 |
豪夫迈‧罗氏有限公司 |
结合间皮素和cd3的双特异性t细胞活化性抗原结合分子
|
|
EP3356407B1
(en)
|
2015-10-02 |
2021-11-03 |
F. Hoffmann-La Roche AG |
Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
|
|
WO2017055385A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
|
|
CN108139394B
(zh)
|
2015-10-02 |
2020-10-30 |
豪夫迈·罗氏有限公司 |
用于确定同时结合的基于细胞的fret测定法
|
|
CN107949574A
(zh)
|
2015-10-02 |
2018-04-20 |
豪夫迈·罗氏有限公司 |
双特异性t细胞活化性抗原结合分子
|
|
WO2017055392A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
|
|
EP3150637A1
(en)
|
2015-10-02 |
2017-04-05 |
F. Hoffmann-La Roche AG |
Multispecific antibodies
|
|
WO2017055393A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
|
|
MA43025A
(fr)
|
2015-10-02 |
2021-05-26 |
Hoffmann La Roche |
Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t anti-ceaxcd3
|
|
US20180282410A1
(en)
|
2015-10-02 |
2018-10-04 |
Hoffmann-La Roche Inc. |
Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
|
|
DK3365373T3
(da)
|
2015-10-23 |
2021-04-06 |
Merus Nv |
Bindingsmolekyler, der hæmmer cancervækst
|
|
KR20240163189A
(ko)
|
2015-10-29 |
2024-11-18 |
에프. 호프만-라 로슈 아게 |
항-변이체 fc-부위 항체 및 사용 방법
|
|
JP2018534933A
(ja)
|
2015-11-02 |
2018-11-29 |
ヤンセン ファーマシューティカ エヌ．ベー． |
抗ｉｌ１ｒａｐ抗体、ｉｌ１ｒａｐとｃｄ３を結合する二重特異性抗原結合分子、及びその使用
|
|
EP4046655A1
(en)
|
2015-11-03 |
2022-08-24 |
Janssen Biotech, Inc. |
Antibodies specifically binding pd-1 and their uses
|
|
AU2016350717B2
(en)
|
2015-11-03 |
2023-08-10 |
Janssen Biotech, Inc. |
Subcutaneous formulations of anti-CD38 antibodies and their uses
|
|
JP6931329B2
(ja)
|
2015-11-18 |
2021-09-01 |
中外製薬株式会社 |
免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
|
|
WO2017086419A1
(ja)
|
2015-11-18 |
2017-05-26 |
中外製薬株式会社 |
液性免疫応答の増強方法
|
|
CA3007031A1
(en)
|
2015-12-01 |
2017-06-08 |
Genmab B.V. |
Anti-death receptor antibodies and methods of use thereof
|
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
|
CA2997406C
(en)
|
2015-12-09 |
2024-05-28 |
F. Hoffmann-La Roche Ag |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies or cytokine release
|
|
BR112018012344A2
(pt)
|
2015-12-17 |
2018-12-04 |
Janssen Biotech Inc |
anticorpos que se ligam especificamente a hla-dr e seus usos
|
|
JP2019503349A
(ja)
|
2015-12-17 |
2019-02-07 |
ノバルティス アーゲー |
Ｐｄ−１に対する抗体分子およびその使用
|
|
JP2019502695A
(ja)
|
2015-12-17 |
2019-01-31 |
ノバルティス アーゲー |
ＰＤ−１に対する抗体分子とＣ−Ｍｅｔ阻害剤との組合せおよびその使用
|
|
WO2017110980A1
(ja)
|
2015-12-25 |
2017-06-29 |
中外製薬株式会社 |
増強された活性を有する抗体及びその改変方法
|
|
CN108368166B
(zh)
|
2015-12-28 |
2023-03-28 |
中外制药株式会社 |
提高含fc区多肽纯化效率的方法
|
|
BR112018011029A2
(pt)
|
2016-01-08 |
2018-11-21 |
Hoffmann La Roche |
métodos para tratar ou atrasar a progressão do câncer e para melhorar a função imune em um indivíduo com câncer, usos de um antagonista de ligação e de um anticorpo biespecífico, composições e kits
|
|
WO2017125897A1
(en)
|
2016-01-21 |
2017-07-27 |
Novartis Ag |
Multispecific molecules targeting cll-1
|
|
CN109073635A
(zh)
*
|
2016-01-25 |
2018-12-21 |
豪夫迈·罗氏有限公司 |
用于测定t细胞依赖性双特异性抗体的方法
|
|
EP3423482A1
(en)
|
2016-03-04 |
2019-01-09 |
Novartis AG |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
|
RU2746754C2
(ru)
|
2016-03-14 |
2021-04-20 |
Чугаи Сейяку Кабусики Кайся |
Индуцирующее повреждение клеток терапевтическое лекарственное средство, предназначенное для противораковой терапии
|
|
EP3433281A1
(en)
|
2016-03-21 |
2019-01-30 |
Elstar Therapeutics, Inc. |
Multispecific and multifunctional molecules and uses thereof
|
|
MY198233A
(en)
|
2016-03-22 |
2023-08-15 |
Hoffmann La Roche |
Protease-Activated T Cell Bispecific Molecules
|
|
WO2017165683A1
(en)
|
2016-03-23 |
2017-09-28 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
|
PL3443096T3
(pl)
|
2016-04-15 |
2023-06-19 |
Novartis Ag |
Kompozycje i sposoby do selektywnej ekspresji chimerycznych receptorów antygenowych
|
|
JP7320943B2
(ja)
|
2016-04-28 |
2023-08-04 |
中外製薬株式会社 |
抗体含有製剤
|
|
CN109071635B
(zh)
|
2016-05-02 |
2023-09-01 |
豪夫迈·罗氏有限公司 |
Contorsbody－单链靶标结合物
|
|
CA3059010A1
(en)
|
2016-06-02 |
2018-12-06 |
F. Hoffmann-La Roche Ag |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
|
EP3464375A2
(en)
|
2016-06-02 |
2019-04-10 |
Novartis AG |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
|
KR20230047507A
(ko)
|
2016-06-27 |
2023-04-07 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
암 치료 조합
|
|
JP2019527678A
(ja)
|
2016-06-28 |
2019-10-03 |
ユーエムセー・ユトレヒト・ホールディング・ベー・フェー |
ＣＤ３８に特異的に結合する抗体によるＩｇＥ媒介疾患の治療
|
|
EP3478717B1
(en)
|
2016-07-04 |
2022-01-05 |
F. Hoffmann-La Roche AG |
Novel antibody format
|
|
EA201990293A1
(ru)
|
2016-07-14 |
2019-07-31 |
Генмаб А/С |
Мультиспецифичные антитела против cd40 и cd137
|
|
AU2017295886C1
(en)
|
2016-07-15 |
2024-05-16 |
Novartis Ag |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
|
TWI781108B
(zh)
|
2016-07-20 |
2022-10-21 |
比利時商健生藥品公司 |
抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
|
|
TW202508628A
(zh)
|
2016-07-28 |
2025-03-01 |
瑞士商諾華公司 |
嵌合抗原受體及pd-1抑制劑之組合療法
|
|
RU2019105693A
(ru)
|
2016-08-01 |
2020-09-01 |
Новартис Аг |
Лечение рака с применением химерного антигенного рецептора в комбинации с ингибитором молекулы, способствующей фенотипу m2 макрофага
|
|
MA45919A
(fr)
|
2016-08-12 |
2019-06-19 |
Janssen Biotech Inc |
Conception d'anticorps modifiés et d'autres molécules contenant un domaine fc présentant des fonctions d'agonisme et d'effecteur améliorées
|
|
WO2018031400A1
(en)
|
2016-08-12 |
2018-02-15 |
Janssen Biotech, Inc. |
Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
|
|
CN109791149A
(zh)
|
2016-09-30 |
2019-05-21 |
豪夫迈·罗氏有限公司 |
用于功能分析多特异性分子的基于spr的双重结合测定法
|
|
PL3519437T3
(pl)
|
2016-09-30 |
2022-01-17 |
F. Hoffmann-La Roche Ag |
Przeciwciała dwuswoiste przeciwko p95HER2
|
|
EP3523331A1
(en)
|
2016-10-07 |
2019-08-14 |
Novartis AG |
Chimeric antigen receptors for the treatment of cancer
|
|
JOP20190095A1
(ar)
|
2016-10-27 |
2019-04-28 |
Janssen Pharmaceutica Nv |
مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y
|
|
CA3041988A1
(en)
|
2016-11-01 |
2018-05-11 |
Genmab B.V. |
Polypeptide variants and uses thereof
|
|
WO2018093821A1
(en)
|
2016-11-15 |
2018-05-24 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
|
CN110177571B
(zh)
*
|
2016-11-18 |
2024-05-24 |
加利福尼亚大学董事会 |
工程化抗体及其用途
|
|
TW201829463A
(zh)
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
|
KR20190080949A
(ko)
|
2016-11-23 |
2019-07-08 |
바이오버라티브 테라퓨틱스 인크. |
응고 인자 ｉｘ 및 응고 인자 ｘ에 결합하는 이중특이적 항체
|
|
EP3574005B1
(en)
|
2017-01-26 |
2021-12-15 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
|
WO2018147960A1
(en)
|
2017-02-08 |
2018-08-16 |
Imaginab, Inc. |
Extension sequences for diabodies
|
|
MA47449A
(fr)
|
2017-02-10 |
2019-12-18 |
Genmab Bv |
Variants polypeptidiques et ses utilisations
|
|
US20200291089A1
(en)
|
2017-02-16 |
2020-09-17 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
|
TW201834688A
(zh)
*
|
2017-02-24 |
2018-10-01 |
日商中外製藥股份有限公司 |
藥學組成物、抗原結合分子、治療方法以及篩選方法
|
|
WO2018158719A1
(en)
|
2017-03-02 |
2018-09-07 |
Novartis Ag |
Engineered heterodimeric proteins
|
|
SG11201908088RA
(en)
|
2017-03-09 |
2019-10-30 |
Genmab As |
Antibodies against pd-l1
|
|
CN110402253B
(zh)
|
2017-03-10 |
2024-01-05 |
豪夫迈·罗氏有限公司 |
用于生产多特异性抗体的方法
|
|
EP3600413A1
(en)
|
2017-03-31 |
2020-02-05 |
Merus N.V. |
Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
|
|
IL269645B2
(en)
|
2017-03-31 |
2025-05-01 |
Genmab Holding B V |
Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
|
|
WO2018184964A1
(en)
|
2017-04-03 |
2018-10-11 |
F. Hoffmann-La Roche Ag |
Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
|
|
JP7148539B2
(ja)
|
2017-04-03 |
2022-10-05 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
免疫抱合体
|
|
RU2019134462A
(ru)
|
2017-04-03 |
2021-05-05 |
Ф. Хоффманн-Ля Рош Аг |
Антитела, связывающиеся с steap-1
|
|
AU2018249493A1
(en)
|
2017-04-03 |
2019-09-19 |
Oncxerna Therapeutics, Inc. |
Methods for treating cancer using PS-targeting antibodies with immuno-oncology agents
|
|
IL268527B2
(en)
|
2017-04-05 |
2024-03-01 |
Hoffmann La Roche |
Bispecific antibodies specifically binding to pd1 and lag3
|
|
US11325982B2
(en)
*
|
2017-04-09 |
2022-05-10 |
Xuanzhu Biopharmaceutical Co., Ltd. |
Biparatopic and multiparatopic antibodies with common light chain and method of use
|
|
CA3058279A1
(en)
|
2017-04-13 |
2018-10-18 |
F.Hoffmann-La Roche Ag |
An interleukin-2 immunoconjugate, a cd40 agonist, and optionally a pd-1 axis binding antagonist for use in methods of treating cancer
|
|
WO2018201051A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
WO2018201056A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
CN108866635B
(zh)
|
2017-05-09 |
2021-11-26 |
安升（上海）医药科技有限公司 |
多特异性蛋白药物及其文库、以及制备方法和应用
|
|
AU2018271157C1
(en)
|
2017-05-17 |
2021-11-18 |
Merus N.V. |
Combination of an ErbB-2/ErbB-3 bispecific antibody with endocrine therapy for breast cancer
|
|
JP2020522254A
(ja)
|
2017-05-31 |
2020-07-30 |
エルスター セラピューティクス， インコーポレイテッド |
骨髄増殖性白血病（ｍｐｌ）タンパク質に結合する多特異性分子およびその使用
|
|
JP7235733B2
(ja)
|
2017-06-05 |
2023-03-08 |
ヤンセン バイオテツク，インコーポレーテツド |
Ｐｄ－１に特異的に結合する抗体、及び使用方法
|
|
AU2018281045A1
(en)
|
2017-06-05 |
2019-12-12 |
Janssen Biotech, Inc. |
Engineered multispecific antibodies and other multimeric proteins with asymmetrical CH2-CH3 region mutations
|
|
WO2018224609A1
(en)
|
2017-06-07 |
2018-12-13 |
Genmab B.V. |
Therapeutic antibodies based on mutated igg hexamers
|
|
PE20200717A1
(es)
|
2017-06-22 |
2020-07-21 |
Novartis Ag |
Moleculas de anticuerpo que se unen a cd73 y usos de las mismas
|
|
AU2018292618A1
(en)
|
2017-06-27 |
2019-12-19 |
Novartis Ag |
Dosage regimens for anti-TIM-3 antibodies and uses thereof
|
|
AR112603A1
(es)
|
2017-07-10 |
2019-11-20 |
Lilly Co Eli |
Anticuerpos biespecíficos inhibidores de punto de control
|
|
CN111278858B
(zh)
|
2017-07-11 |
2024-07-23 |
指南针制药有限责任公司 |
结合人cd137的激动剂抗体及其用途
|
|
KR20200031659A
(ko)
|
2017-07-20 |
2020-03-24 |
노파르티스 아게 |
항-lag-3 항체의 투여 요법 및 그의 용도
|
|
KR102758346B1
(ko)
|
2017-08-04 |
2025-01-24 |
젠맵 에이/에스 |
Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도
|
|
CN118562014A
(zh)
|
2017-08-09 |
2024-08-30 |
美勒斯公司 |
结合EGFR和cMET的抗体
|
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
|
IL273592B2
(en)
|
2017-09-29 |
2025-11-01 |
Chugai Pharmaceutical Co Ltd |
Multispecific antigen-binding molecule having blood coagulation factor viii (fviii) cofactor function-substituting activity, and pharmaceutical formulation containing said molecule as active ingredient
|
|
KR20200067197A
(ko)
|
2017-10-20 |
2020-06-11 |
에프. 호프만-라 로슈 아게 |
단일특이적 항체로부터 다중특이적 항체의 생성 방법
|
|
IL274071B2
(en)
|
2017-10-30 |
2025-10-01 |
Hoffmann La Roche |
Method for generating in vivo multispecific antibodies from monospecific antibodies
|
|
US11718679B2
(en)
|
2017-10-31 |
2023-08-08 |
Compass Therapeutics Llc |
CD137 antibodies and PD-1 antagonists and uses thereof
|
|
EP3704146B1
(en)
|
2017-11-01 |
2021-12-15 |
F. Hoffmann-La Roche AG |
Trifab-contorsbody
|
|
WO2019086394A1
(en)
|
2017-11-01 |
2019-05-09 |
F. Hoffmann-La Roche Ag |
The compbody - a multivalent target binder
|
|
MX2020003472A
(es)
|
2017-11-01 |
2020-08-03 |
Chugai Pharmaceutical Co Ltd |
Variante e isoforma de anticuerpos con actividad biologica reducida.
|
|
MA50505A
(fr)
|
2017-11-01 |
2020-09-09 |
Hoffmann La Roche |
Anticorps 2 + 1 bispécifiques (contorsbodies)
|
|
EP3703746A1
(en)
|
2017-11-01 |
2020-09-09 |
F. Hoffmann-La Roche AG |
Novel tnf family ligand trimer-containing antigen binding molecules
|
|
MX2020004756A
(es)
|
2017-11-16 |
2020-08-20 |
Novartis Ag |
Terapias de combinacion.
|
|
EP3713961A2
(en)
|
2017-11-20 |
2020-09-30 |
Compass Therapeutics LLC |
Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
|
JP6522727B2
(ja)
*
|
2017-12-15 |
2019-05-29 |
矢崎総業株式会社 |
メッキ繊維及びワイヤハーネス
|
|
CN111699003B
(zh)
|
2017-12-19 |
2024-05-03 |
瑟罗泽恩奥普瑞汀公司 |
抗lrp5/6抗体和使用方法
|
|
CN118271444A
(zh)
|
2017-12-19 |
2024-07-02 |
瑟罗泽恩奥普瑞汀公司 |
Wnt替代分子和其用途
|
|
AU2018393074B2
(en)
|
2017-12-19 |
2025-10-23 |
Surrozen Operating, Inc. |
Anti-frizzled antibodies and methods of use
|
|
WO2019122052A2
(en)
|
2017-12-21 |
2019-06-27 |
F. Hoffmann-La Roche Ag |
Antibodies binding to hla-a2/wt1
|
|
JP7074859B2
(ja)
|
2017-12-22 |
2022-05-24 |
エフ．ホフマン－ラ ロシュ アーゲー |
疎水性相互作用クロマトグラフィーによる軽鎖誤対合抗体変種の枯渇の方法
|
|
WO2019139987A1
(en)
|
2018-01-09 |
2019-07-18 |
Elstar Therapeutics, Inc. |
Calreticulin binding constructs and engineered t cells for the treatment of diseases
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
WO2019145455A1
(en)
|
2018-01-24 |
2019-08-01 |
Genmab B.V. |
Polypeptide variants and uses thereof
|
|
EP3746116A1
(en)
|
2018-01-31 |
2020-12-09 |
Novartis AG |
Combination therapy using a chimeric antigen receptor
|
|
CN119909169A
(zh)
|
2018-02-06 |
2025-05-02 |
豪夫迈·罗氏有限公司 |
眼科疾病的治疗
|
|
SG11202007390YA
(en)
|
2018-02-08 |
2020-08-28 |
Genentech Inc |
Bispecific antigen-binding molecules and methods of use
|
|
TWI829667B
(zh)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
|
WO2019160007A1
(ja)
|
2018-02-14 |
2019-08-22 |
中外製薬株式会社 |
抗原結合分子および組合せ
|
|
CN111971298B
(zh)
|
2018-03-12 |
2025-06-20 |
健玛保 |
抗体
|
|
WO2019178364A2
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
US12152073B2
(en)
|
2018-03-14 |
2024-11-26 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
|
AR114789A1
(es)
|
2018-04-18 |
2020-10-14 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de los mismos
|
|
AR115052A1
(es)
|
2018-04-18 |
2020-11-25 |
Hoffmann La Roche |
Anticuerpos multiespecíficos y utilización de los mismos
|
|
US20210047405A1
(en)
|
2018-04-27 |
2021-02-18 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
WO2019211472A1
(en)
|
2018-05-03 |
2019-11-07 |
Genmab B.V. |
Antibody variant combinations and uses thereof
|
|
CN108752478B
(zh)
*
|
2018-05-03 |
2021-05-25 |
沣潮医药科技（上海）有限公司 |
全人源抗人EGFR和Notch2/3多特异性抗体、其制备方法及用途
|
|
MY203469A
(en)
|
2018-05-16 |
2024-06-28 |
Stichting Vumc |
Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
|
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
|
WO2019226617A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Compositions and methods for enhancing the killing of target cells by nk cells
|
|
BR112020023872A2
(pt)
|
2018-05-24 |
2021-02-17 |
Janssen Biotech, Inc. |
agentes de ligação de psma e seus usos
|
|
SMT202500221T1
(it)
|
2018-05-24 |
2025-07-22 |
Janssen Biotech Inc |
Anticorpi anti-cd3 e usi di essi
|
|
US11866499B2
(en)
|
2018-05-24 |
2024-01-09 |
Janssen Biotech, Inc. |
Monospecific and multispecific anti-TMEFF2 antibodies and their uses
|
|
JOP20190116A1
(ar)
|
2018-05-24 |
2019-11-24 |
Janssen Biotech Inc |
الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
|
|
WO2019227003A1
(en)
|
2018-05-25 |
2019-11-28 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
JP7646361B2
(ja)
|
2018-06-01 |
2025-03-17 |
コンピュジェン リミテッド |
抗ｐｖｒｉｇ／抗ｔｉｇｉｔ二重特異性抗体および使用方法
|
|
CA3100724A1
(en)
|
2018-06-13 |
2019-12-19 |
Novartis Ag |
B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
|
|
CA3104295A1
(en)
|
2018-06-19 |
2019-12-26 |
Atarga, Llc |
Antibody molecules to complement component 5 and uses thereof
|
|
MA52951A
(fr)
|
2018-06-22 |
2021-04-28 |
Genmab Holding B V |
Anticorps anti-cd37 et anticorps anti-cd20, compositions et méthodes d'utilisation de ceux-ci
|
|
CN112955465A
(zh)
|
2018-07-03 |
2021-06-11 |
马伦戈治疗公司 |
抗tcr抗体分子及其用途
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
MA53123A
(fr)
|
2018-07-13 |
2021-05-19 |
Genmab As |
Thérapie à médiation par trogocytose utilisant des anticorps cd38
|
|
EP3820900A1
(en)
|
2018-07-13 |
2021-05-19 |
Genmab A/S |
Variants of cd38 antibody and uses thereof
|
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
|
US20210188957A1
(en)
|
2018-08-29 |
2021-06-24 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody half-molecule, and method for inhibiting homodimer formation of antibody half-molecule
|
|
EP3860715A1
(en)
|
2018-10-04 |
2021-08-11 |
Genmab Holding B.V. |
Pharmaceutical compositions comprising bispecific anti-cd37 antibodies
|
|
BR112021007946A2
(pt)
|
2018-10-29 |
2021-08-03 |
F. Hoffmann-La Roche Ag |
formulação de anticorpo
|
|
BR112021008774A2
(pt)
|
2018-11-06 |
2021-11-30 |
BioNTech SE |
Formulação farmacêutica, agente de ligação, métodos para tratamento de uma doença, para produzir uma formulação farmacêutica, para induzir a morte celular ou inibir o crescimento e/ou a proliferação de uma célula tumoral, e, uso de uma formulação farmacêutica
|
|
US11046769B2
(en)
|
2018-11-13 |
2021-06-29 |
Compass Therapeutics Llc |
Multispecific binding constructs against checkpoint molecules and uses thereof
|
|
JP2022513708A
(ja)
|
2018-12-05 |
2022-02-09 |
モルフォシス・アーゲー |
多重特異性抗原結合分子
|
|
TWI874341B
(zh)
|
2018-12-18 |
2025-03-01 |
美商健生生物科技公司 |
產生異二聚體抗體之方法
|
|
WO2020128972A1
(en)
|
2018-12-20 |
2020-06-25 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
WO2020128892A1
(en)
|
2018-12-20 |
2020-06-25 |
Novartis Ag |
Extended low dose regimens for mdm2 inhibitors
|
|
KR20240155361A
(ko)
|
2018-12-21 |
2024-10-28 |
에프. 호프만-라 로슈 아게 |
Cd3에 결합하는 항체
|
|
SG11202106393SA
(en)
|
2018-12-24 |
2021-07-29 |
Sanofi Sa |
Pseudofab-based multispecific binding proteins
|
|
EP3902560A1
(en)
|
2018-12-28 |
2021-11-03 |
F. Hoffmann-La Roche AG |
A peptide-mhc-i-antibody fusion protein for therapeutic use in a patient with amplified immune response
|
|
TWI852977B
(zh)
|
2019-01-10 |
2024-08-21 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
|
AU2020208828A1
(en)
|
2019-01-15 |
2021-08-05 |
Janssen Biotech, Inc. |
Anti-TNF antibody compositions and methods for the treatment of juvenile idiopathic arthritis
|
|
EP3911677A1
(en)
|
2019-01-18 |
2021-11-24 |
Janssen Biotech, Inc. |
Gprc5d chimeric antigen receptors and cells expressing the same
|
|
US20220064278A1
(en)
|
2019-01-23 |
2022-03-03 |
Janssen Biotech, Inc. |
Anti-TNF Antibody Compositions for Use in Methods for the Treatment of Psoriatic Arthritis
|
|
US10871640B2
(en)
|
2019-02-15 |
2020-12-22 |
Perkinelmer Cellular Technologies Germany Gmbh |
Methods and systems for automated imaging of three-dimensional objects
|
|
ES3032659T3
(en)
|
2019-02-15 |
2025-07-23 |
Novartis Ag |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
AU2020222346B2
(en)
|
2019-02-15 |
2021-12-09 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
CN114127111B
(zh)
|
2019-02-21 |
2024-09-10 |
马伦戈治疗公司 |
与nkp30结合的抗体分子及其用途
|
|
JP7737306B2
(ja)
|
2019-02-21 |
2025-09-10 |
マレンゴ・セラピューティクス，インコーポレーテッド |
Ｔ細胞に結合する多機能性分子および自己免疫障害を処置するためのその使用
|
|
CA3130754A1
(en)
|
2019-02-21 |
2020-08-27 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
|
AU2020226904B2
(en)
|
2019-02-21 |
2025-05-01 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
|
CN114127113A
(zh)
|
2019-02-21 |
2022-03-01 |
马伦戈治疗公司 |
与钙网蛋白结合的多功能分子及其用途
|
|
WO2020172553A1
(en)
|
2019-02-22 |
2020-08-27 |
Novartis Ag |
Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
|
|
CN113840842A
(zh)
|
2019-02-26 |
2021-12-24 |
詹森生物科技公司 |
利用双特异性抗EGFR/c-Met抗体的联合疗法和患者分层
|
|
MX2021010857A
(es)
|
2019-03-11 |
2021-12-15 |
Janssen Biotech Inc |
Anticuerpos biespecificos anti-v(beta17)/anti-cd123.
|
|
CA3133383A1
(en)
|
2019-03-14 |
2020-09-17 |
Janssen Biotech, Inc. |
Methods for producing anti-tnf antibody compositions
|
|
US20200291107A1
(en)
|
2019-03-14 |
2020-09-17 |
Janssen Biotech, Inc. |
Manufacturing Methods for Producing Anti-IL12/IL23 Antibody Compositions
|
|
MA55282A
(fr)
|
2019-03-14 |
2022-01-19 |
Janssen Biotech Inc |
Procédés de fabrication pour la production de compositions d'anticorps anti-tnf
|
|
JP7662529B2
(ja)
|
2019-03-14 |
2025-04-15 |
ヤンセン バイオテツク，インコーポレーテツド |
抗ｔｎｆ抗体組成物を産生するための方法
|
|
WO2020200941A1
(en)
|
2019-03-29 |
2020-10-08 |
F. Hoffmann-La Roche Ag |
Spr-based binding assay for the functional analysis of multivalent molecules
|
|
JP7412440B2
(ja)
|
2019-03-29 |
2024-01-12 |
エフ． ホフマン－ラ ロシュ アーゲー |
アビド結合多重特異性抗体を作製する方法
|
|
CA3135430A1
(en)
|
2019-03-29 |
2020-10-08 |
Atarga, Llc |
Anti fgf23 antibody
|
|
KR20220002899A
(ko)
|
2019-04-19 |
2022-01-07 |
얀센 바이오테크 인코포레이티드 |
항-psma/cd3 항체로 전립선암을 치료하는 방법
|
|
CA3133898A1
(en)
|
2019-04-25 |
2020-10-29 |
Ulrich Brinkmann |
Activatable therapeutic multispecific polypeptides with extended half-life
|
|
JP7688584B2
(ja)
|
2019-04-25 |
2025-06-04 |
エフ． ホフマン－ラ ロシュ アーゲー |
ポリペプチド鎖の交換により活性化される治療用多重特異性ポリペプチド
|
|
CN113728002B
(zh)
|
2019-04-25 |
2024-11-12 |
豪夫迈·罗氏有限公司 |
通过多肽链交换产生抗体衍生的多肽
|
|
BR112021022089A2
(pt)
|
2019-05-08 |
2022-02-08 |
Janssen Biotech Inc |
Materiais e métodos para modulação da imunidade mediada por células t
|
|
WO2020225456A1
(en)
|
2019-05-09 |
2020-11-12 |
Genmab B.V. |
Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancer
|
|
EP3969907B1
(en)
|
2019-05-13 |
2025-09-24 |
F. Hoffmann-La Roche AG |
Interference-suppressed pharmacokinetic immunoassay
|
|
JOP20210304A1
(ar)
|
2019-05-14 |
2023-01-30 |
Janssen Biotech Inc |
علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث
|
|
CN113939531A
(zh)
|
2019-06-03 |
2022-01-14 |
詹森生物科技公司 |
用于治疗银屑病关节炎的抗tnf抗体组合物和方法
|
|
KR20220024460A
(ko)
*
|
2019-06-11 |
2022-03-03 |
안틀라 테라퓨틱스 아이엔씨. |
다가 fzd 및 wnt 결합 분자 및 이의 용도
|
|
CA3140297A1
(en)
|
2019-06-19 |
2020-12-24 |
Simon Auslaender |
Method for the generation of a protein expressing cell by targeted integration using cre mrna
|
|
HUE071032T2
(hu)
|
2019-06-26 |
2025-07-28 |
Hoffmann La Roche |
Emlõs sejtvonalak SIRT-1 gén kiiktatásával
|
|
WO2021001289A1
(en)
|
2019-07-02 |
2021-01-07 |
F. Hoffmann-La Roche Ag |
Immunoconjugates comprising a mutant interleukin-2 and an anti-cd8 antibody
|
|
WO2021006328A1
(en)
|
2019-07-10 |
2021-01-14 |
Chugai Seiyaku Kabushiki Kaisha |
Claudin-6 binding molecules and uses thereof
|
|
US12435131B2
(en)
|
2019-07-11 |
2025-10-07 |
Tavotek Biotherapeutics (Hong Kong) Limited |
Agents that interfere with thymic stromal lymphopoietin (TSLP)-receptor signaling
|
|
BR112022000145A2
(pt)
|
2019-07-12 |
2022-02-22 |
Janssen Pharmaceutica Nv |
Agentes de ligação e usos dos mesmos
|
|
AR119393A1
(es)
|
2019-07-15 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos que se unen a nkg2d
|
|
CN114375302B
(zh)
|
2019-07-26 |
2024-12-24 |
詹森生物科技公司 |
包含激肽释放酶相关肽酶2抗原结合结构域的蛋白质及其用途
|
|
MY206610A
(en)
|
2019-07-31 |
2024-12-26 |
Hoffmann La Roche |
Antibodies binding to gprc5d
|
|
JP2022543551A
(ja)
|
2019-07-31 |
2022-10-13 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｇｐｒｃ５ｄに結合する抗体
|
|
TW202120537A
(zh)
|
2019-08-15 |
2021-06-01 |
美商健生生物科技公司 |
用於經改善的單鏈可變片段之材料及方法
|
|
EP4048285A1
(en)
|
2019-10-21 |
2022-08-31 |
Novartis AG |
Tim-3 inhibitors and uses thereof
|
|
WO2021079188A1
(en)
|
2019-10-21 |
2021-04-29 |
Novartis Ag |
Combination therapies with venetoclax and tim-3 inhibitors
|
|
EP4055046A1
(en)
|
2019-11-06 |
2022-09-14 |
Genmab B.V. |
Antibody variant combinations and uses thereof
|
|
WO2021099944A1
(en)
|
2019-11-18 |
2021-05-27 |
Janssen Biotech, Inc. |
Anti-cd79 chimeric antigen receptors, car-t cells, and uses thereof
|
|
IL293215A
(en)
|
2019-11-26 |
2022-07-01 |
Novartis Ag |
Chimeric antigen receptors that bind bcma and cd19 and their uses
|
|
CN110964119A
(zh)
*
|
2019-12-05 |
2020-04-07 |
沣潮医药科技（上海）有限公司 |
抗疟二聚体免疫粘附素、药物组合物和用途
|
|
CN115087670B
(zh)
|
2019-12-11 |
2025-10-28 |
西拉格国际有限责任公司 |
包含ltbr和edb结合结构域的多特异性结合分子及其用途
|
|
BR112022011854A2
(pt)
|
2019-12-18 |
2022-09-06 |
Hoffmann La Roche |
Anticorpos, polinucleotídeo isolado, célula hospedeira, métodos para produzir um anticorpo e para tratar uma doença, composição farmacêutica, usos do anticorpo e invenção
|
|
JP7415005B2
(ja)
|
2019-12-18 |
2024-01-16 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性抗ｃｃｌ２抗体
|
|
BR112022011902A2
(pt)
|
2019-12-20 |
2022-09-06 |
Novartis Ag |
Terapias de combinação
|
|
US11913945B2
(en)
|
2020-01-02 |
2024-02-27 |
Hoffmann-La Roche Inc. |
Method for determining the amount of a therapeutic antibody in the brain
|
|
CN116234829A
(zh)
|
2020-01-03 |
2023-06-06 |
马伦戈治疗公司 |
抗tcr抗体分子及其用途
|
|
EP4084821A4
(en)
|
2020-01-03 |
2024-04-24 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
|
CA3165660A1
(en)
|
2020-01-16 |
2021-07-22 |
Genmab A/S |
Formulations of cd38 antibodies and uses thereof
|
|
WO2021144657A1
(en)
|
2020-01-17 |
2021-07-22 |
Novartis Ag |
Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
|
|
US20210222244A1
(en)
|
2020-01-17 |
2021-07-22 |
Becton, Dickinson And Company |
Methods and compositions for single cell secretomics
|
|
JP2023512071A
(ja)
|
2020-01-30 |
2023-03-23 |
ウモジャ バイオファーマ， インコーポレイテッド |
二特異性形質導入エンハンサー
|
|
WO2021155916A1
(en)
|
2020-02-04 |
2021-08-12 |
BioNTech SE |
Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137
|
|
JOP20220184A1
(ar)
|
2020-02-12 |
2023-01-30 |
Janssen Biotech Inc |
علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14
|
|
TW202144388A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在卵巢癌中表現之新抗原及其用途
|
|
TW202144389A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在多發性骨髓瘤中表現之新抗原及其用途
|
|
CA3173737A1
(en)
|
2020-02-27 |
2021-09-02 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
JOP20220220A1
(ar)
|
2020-03-13 |
2023-01-30 |
Janssen Biotech Inc |
مواد وطرق لربط لكتين شبيه بالجوبيولين المناعي بحمض سياليك
|
|
TW202200624A
(zh)
|
2020-03-18 |
2022-01-01 |
丹麥商珍美寶股份有限公司 |
抗體
|
|
AU2021257848A1
(en)
|
2020-04-15 |
2022-12-01 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
|
MX2022012541A
(es)
|
2020-04-15 |
2022-11-07 |
Hoffmann La Roche |
Inmunoconjugados.
|
|
EP4136121B1
(en)
|
2020-04-16 |
2025-05-28 |
Janssen Biotech, Inc. |
Systems, materials, and methods for reversed-phase high performance liquid chromatography (rp-hplc) for monitoring formation of multi-specific molecules
|
|
AU2021261420A1
(en)
|
2020-04-24 |
2022-12-01 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
|
US20230172923A1
(en)
|
2020-04-30 |
2023-06-08 |
Bristol-Myers Squibb Company |
Methods of treating cytokine-related adverse events
|
|
CN115916166A
(zh)
|
2020-05-08 |
2023-04-04 |
健玛保 |
针对cd3和cd20的双特异性抗体
|
|
CA3182697A1
(en)
|
2020-05-11 |
2021-11-18 |
Janssen Biotech, Inc. |
Methods for treating multiple myeloma
|
|
BR112022022614A2
(pt)
|
2020-05-11 |
2023-02-07 |
Hoffmann La Roche |
Métodos para estimular uma resposta imune, melhorar uma imunoterapia, tratar uma doença, reduzir crescimento tumoral, produzir um imunoconjugado e produzir uma composição, método de vacinação, imunoconjugados, composição, usos e kits
|
|
WO2021240388A1
(en)
|
2020-05-27 |
2021-12-02 |
Janssen Biotech, Inc. |
Proteins comprising cd3 antigen binding domains and uses thereof
|
|
GB202008860D0
(en)
|
2020-06-11 |
2020-07-29 |
Univ Oxford Innovation Ltd |
BTLA antibodies
|
|
CA3176579A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3
|
|
US11780920B2
(en)
|
2020-06-19 |
2023-10-10 |
Hoffmann-La Roche Inc. |
Antibodies binding to CD3 and CD19
|
|
MX2022015887A
(es)
|
2020-06-19 |
2023-01-24 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y folr1.
|
|
WO2021255146A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cea
|
|
PE20230470A1
(es)
|
2020-06-19 |
2023-03-14 |
Hoffmann La Roche |
Moleculas de union al dominio fc de activacion inmunitaria
|
|
CN115916199A
(zh)
|
2020-06-23 |
2023-04-04 |
诺华股份有限公司 |
包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
|
|
US12295997B2
(en)
|
2020-07-06 |
2025-05-13 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
|
CR20230009A
(es)
|
2020-07-16 |
2023-01-25 |
Novartis Ag |
Anticuerpos anti-betacelulina, fragmentos de los mismos, y moléculas de unión multiespecíficas
|
|
EP4185388A1
(en)
|
2020-07-23 |
2023-05-31 |
Genmab B.V. |
A combination of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma
|
|
WO2022026592A2
(en)
|
2020-07-28 |
2022-02-03 |
Celltas Bio, Inc. |
Antibody molecules to coronavirus and uses thereof
|
|
KR20230041819A
(ko)
|
2020-07-29 |
2023-03-24 |
얀센 바이오테크 인코포레이티드 |
Hla-g 항원-결합 도메인을 포함하는 단백질 및 이의 용도
|
|
CA3190174A1
(en)
|
2020-08-03 |
2022-02-10 |
Janssen Biotech, Inc. |
Materials and methods for multidirectional biotransportation in virotherapeutics
|
|
CN116134027B
(zh)
|
2020-08-03 |
2025-01-24 |
诺华股份有限公司 |
杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
|
|
KR20230065256A
(ko)
|
2020-08-06 |
2023-05-11 |
비온테크 에스이 |
코로나바이러스 s 단백질용 결합제
|
|
UY39373A
(es)
|
2020-08-10 |
2022-02-25 |
Janssen Biotech Inc |
Materiales y métodos para producir linfocitos específicos de virus diseñados mediante bioingeniería
|
|
AU2021330539A1
(en)
|
2020-08-25 |
2023-05-04 |
Janssen Biotech, Inc. |
Treatment of non-small cell lung cancer with egfr mutations
|
|
EP4204458A4
(en)
|
2020-08-26 |
2024-10-09 |
Marengo Therapeutics, Inc. |
METHODS FOR DETECTION OF TRBC1 OR TRBC2
|
|
GB2616128A
(en)
|
2020-08-26 |
2023-08-30 |
Marengo Therapeutics Inc |
Antibody molecules that bind to NKp30 and uses thereof
|
|
WO2022046920A2
(en)
|
2020-08-26 |
2022-03-03 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
EP4204020A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
|
EP4204021A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
|
US20230310599A1
(en)
|
2020-09-02 |
2023-10-05 |
Genmab A/S |
Antibody therapy
|
|
AU2021342342A1
(en)
|
2020-09-10 |
2023-04-13 |
Genmab A/S |
Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic leukemia
|
|
JP2023542289A
(ja)
|
2020-09-10 |
2023-10-06 |
ジェンマブ エー／エス |
濾胞性リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体
|
|
EP4210744A1
(en)
|
2020-09-10 |
2023-07-19 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
|
|
MX2023002544A
(es)
|
2020-09-10 |
2023-03-14 |
Genmab As |
Anticuerpo biespecifico contra cumulo de diferenciacion 3 (cd3) y cumulo de diferenciacion 20 (cd20) en terapia de combinacion para tratar linfoma folicular.
|
|
AU2021342343A1
(en)
|
2020-09-10 |
2023-04-13 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
|
|
WO2022053654A1
(en)
|
2020-09-10 |
2022-03-17 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
|
|
US12448449B2
(en)
|
2020-09-11 |
2025-10-21 |
Janssen Biotech, Inc. |
Immune targeting molecules and uses thereof
|
|
WO2022056192A1
(en)
|
2020-09-11 |
2022-03-17 |
Janssen Biotech, Inc. |
Methods and compositions for modulating beta chain mediated immunity
|
|
MX2023003328A
(es)
|
2020-09-24 |
2023-03-27 |
Hoffmann La Roche |
Lineas de celulas de mamifero con desactivacion genica.
|
|
BR112023005742A2
(pt)
|
2020-10-02 |
2023-05-02 |
Genmab As |
Anticorpo, composição, composição farmacêutica, método para tratar uma doença, ácido nucléico, vetor de expressão, célula, método para produzir um anticorpo, kit de partes, e, anticorpo anti-idiotípico
|
|
CA3198590A1
(en)
|
2020-10-13 |
2022-04-21 |
Rajkumar Ganesan |
Bioengineered t cell mediated immunity, materials and other methods for modulating cluster of differentiation iv &/or viii
|
|
KR20230110523A
(ko)
|
2020-10-22 |
2023-07-24 |
얀센 바이오테크 인코포레이티드 |
델타-유사 리간드 3(dll3) 항원 결합 영역을 포함하는 단백질 및 그의 용도
|
|
WO2022093888A1
(en)
|
2020-10-28 |
2022-05-05 |
Janssen Biotech, Inc. |
Compositions and methods for modulating delta gamma chain mediated immunity
|
|
US12516118B2
(en)
|
2020-11-04 |
2026-01-06 |
Genentech, Inc. |
Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies and anti-CD79b antibody drug conjugates
|
|
MX2023005132A
(es)
|
2020-11-04 |
2023-05-25 |
Genentech Inc |
Dosificacion para el tratamiento con anticuerpos biespecificos anti-cd20/anti-cd3.
|
|
CA3196076A1
(en)
|
2020-11-04 |
2022-05-12 |
Chi-Chung Li |
Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
|
|
KR20230107305A
(ko)
|
2020-11-10 |
2023-07-14 |
상하이 치루 파마슈티컬 리서치 앤 디벨롭먼트 센터 리미티드 |
클라우딘 18a2 및 cd3에 대한 이중특이성 항체 및 이중특이성 항체의 용도
|
|
EP4243857A1
(en)
|
2020-11-13 |
2023-09-20 |
Novartis AG |
Combination therapies with chimeric antigen receptor (car)-expressing cells
|
|
EP4263609A1
(en)
|
2020-12-17 |
2023-10-25 |
F. Hoffmann-La Roche AG |
Anti-hla-g antibodies and use thereof
|
|
WO2022129313A1
(en)
|
2020-12-18 |
2022-06-23 |
F. Hoffmann-La Roche Ag |
Precursor proteins and kit for targeted therapy
|
|
WO2022136140A1
(en)
|
2020-12-22 |
2022-06-30 |
F. Hoffmann-La Roche Ag |
Oligonucleotides targeting xbp1
|
|
WO2022148732A1
(en)
|
2021-01-06 |
2022-07-14 |
F. Hoffmann-La Roche Ag |
Combination therapy employing a pd1-lag3 bispecific antibody and a cd20 t cell bispecific antibody
|
|
WO2022148853A1
(en)
|
2021-01-11 |
2022-07-14 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
|
JP2024504758A
(ja)
|
2021-01-28 |
2024-02-01 |
ヤンセン バイオテツク，インコーポレーテツド |
Ｐｓｍａ結合タンパク質及びその使用
|
|
WO2022162569A1
(en)
|
2021-01-29 |
2022-08-04 |
Novartis Ag |
Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
|
|
US20220267438A1
(en)
|
2021-02-16 |
2022-08-25 |
Janssen Pharmaceutica Nv |
Trispecific antibody targeting bcma, gprc5d, and cd3
|
|
AU2022224508A1
(en)
|
2021-02-16 |
2023-10-05 |
Janssen Biotech, Inc. |
Materials and methods for enhanced linker targeting
|
|
JP2024512240A
(ja)
|
2021-02-18 |
2024-03-19 |
エフ． ホフマン－ラ ロシュ アーゲー |
複雑な多段階の抗体相互作用を解明するための方法
|
|
JP2024509920A
(ja)
|
2021-03-09 |
2024-03-05 |
ヤンセン バイオテツク，インコーポレーテツド |
Ｅｇｆｒ活性化変異を欠くがんの治療
|
|
EP4305056A1
(en)
|
2021-03-12 |
2024-01-17 |
Genmab A/S |
Non-activating antibody variants
|
|
BR112023019484A2
(pt)
|
2021-03-24 |
2023-12-05 |
Janssen Biotech Inc |
Anticorpo triespecífico que tem como alvo cd79b, cd20 e cd3
|
|
CN117098781A
(zh)
|
2021-03-24 |
2023-11-21 |
詹森生物科技公司 |
靶向cd22和cd79b的抗体
|
|
IL306132A
(en)
|
2021-03-24 |
2023-11-01 |
Janssen Biotech Inc |
Proteins containing CD3 antigen binding sites and uses thereof
|
|
JP2024514077A
(ja)
|
2021-03-31 |
2024-03-28 |
江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 |
切断したｔａｃｉポリペプチド及びその融合タンパク質並びに使用
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
GB2623199A
(en)
|
2021-04-08 |
2024-04-10 |
Marengo Therapeutics Inc |
Multifunctional molecules binding to TCR and uses thereof
|
|
KR20240005691A
(ko)
|
2021-04-30 |
2024-01-12 |
에프. 호프만-라 로슈 아게 |
항-cd20/항-cd3 이중특이적 항체 및 항-cd79b 항체 약물 접합체를 이용한 병용 치료를 위한 투약
|
|
EP4329800A1
(en)
|
2021-04-30 |
2024-03-06 |
F. Hoffmann-La Roche AG |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
|
|
MX2023012351A
(es)
|
2021-05-07 |
2023-10-31 |
Genmab As |
Composiciones farmaceuticas que comprenden anticuerpos biespecificos que se unen al inhibidor de la activacion de celulas t que contiene un dominio v-set 1 (b7h4) y cumulo de diferenciacion 3 (cd3).
|
|
BR112023022707A2
(pt)
|
2021-05-12 |
2024-01-16 |
Jiangsu Hengrui Pharmaceuticals Co Ltd |
Molécula de ligação ao antígeno a qual se liga especificamente a rankl e ngf, e seu uso médico
|
|
AU2022273541A1
(en)
|
2021-05-14 |
2023-11-30 |
Genentech, Inc. |
Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
|
|
CN117120478A
(zh)
|
2021-05-14 |
2023-11-24 |
江苏恒瑞医药股份有限公司 |
一种抗原结合分子
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
TW202309094A
(zh)
|
2021-05-18 |
2023-03-01 |
美商健生生物科技公司 |
用於識別癌症患者以進行組合治療之方法
|
|
CN117500829A
(zh)
|
2021-06-18 |
2024-02-02 |
豪夫迈·罗氏有限公司 |
双特异性抗ccl2抗体
|
|
JP2024523438A
(ja)
|
2021-06-21 |
2024-06-28 |
ジェンマブ エー／エス |
Ｃｄ１３７結合物質とｐｄ－ｌ１結合物質の組合せ投薬レジメン
|
|
JP2024525381A
(ja)
|
2021-07-02 |
2024-07-12 |
ジェネンテック， インコーポレイテッド |
がんを治療するための方法及び組成物
|
|
US20230040065A1
(en)
|
2021-07-09 |
2023-02-09 |
Janssen Biotech, Inc. |
Manufacturing Methods for Producing Anti-TNF Antibody Compositions
|
|
US12534524B2
(en)
|
2021-07-09 |
2026-01-27 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-TNF antibody compositions
|
|
US20230038355A1
(en)
|
2021-07-09 |
2023-02-09 |
Janssen Biotech, Inc. |
Manufacturing Methods for Producing Anti-IL12/IL23 Antibody Compositions
|
|
MX2024000501A
(es)
|
2021-07-14 |
2024-01-31 |
Jiangsu Hengrui Pharmaceuticals Co Ltd |
Molecula de union a antigeno que se une especificamente a hgfr y egfr, y su uso farmaceutico.
|
|
EP4373859A1
(en)
|
2021-07-22 |
2024-05-29 |
F. Hoffmann-La Roche AG |
Heterodimeric fc domain antibodies
|
|
CA3227537A1
(en)
|
2021-07-27 |
2023-02-02 |
Morphosys Ag |
Combinations of antigen binding molecules
|
|
WO2023010095A1
(en)
|
2021-07-28 |
2023-02-02 |
F. Hoffmann-La Roche Ag |
Methods and compositions for treating cancer
|
|
US20250277051A1
(en)
|
2021-08-02 |
2025-09-04 |
Hangzhou Unogen Biotech, Ltd |
Anti-cd38 antibodies, anti-cd3 antibodies, and bispecific antibodies, and uses thereof
|
|
US20250270314A1
(en)
|
2021-08-02 |
2025-08-28 |
Tavotek Biotech (Suzhou) Ltd |
Anti-cdh17 monoclonal and bispecific antibodies and uses thereof
|
|
AR127743A1
(es)
|
2021-09-06 |
2024-02-28 |
Genmab Bv |
Anticuerpos capaces de unirse a cd27, variantes y usos de los mismos
|
|
JP2024533457A
(ja)
|
2021-09-13 |
2024-09-12 |
ヤンセン バイオテツク，インコーポレーテツド |
がんの治療のためのＣＤ３３×Ｖδ２多重特異性抗体
|
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
CN117813323A
(zh)
|
2021-09-23 |
2024-04-02 |
江苏恒瑞医药股份有限公司 |
抗klb抗体及用途
|
|
US20250019455A1
(en)
|
2021-09-24 |
2025-01-16 |
Pharmaceutica Nv |
Proteins comprising cd20 binding domains, and uses thereof
|
|
JP2024536870A
(ja)
|
2021-09-30 |
2024-10-08 |
江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 |
抗ｉｌ２３抗体融合タンパク質及び使用
|
|
EP4413039A1
(en)
|
2021-10-08 |
2024-08-14 |
Genmab A/S |
Antibodies binding to cd30 and cd3
|
|
CN118139648A
(zh)
|
2021-10-14 |
2024-06-04 |
豪夫迈·罗氏有限公司 |
用于治疗癌症的替代的PD1-IL7v免疫缀合物
|
|
MX2024004451A
(es)
|
2021-10-14 |
2024-05-08 |
Hoffmann La Roche |
Nuevos inmunoconjugados de interleucina-7.
|
|
WO2023069888A1
(en)
|
2021-10-18 |
2023-04-27 |
Tavotek Biotherapeutics (Hong Kong) Limited |
ANTI-EGFR ANTIBODIES, ANTI-cMET ANTIBODIES, ANTI-VEGF ANTIBODIES, MULTISPECIFIC ANTIBODIES, AND USES THEREOF
|
|
US20250092134A1
(en)
|
2021-11-01 |
2025-03-20 |
Janssen Biotech, Inc. |
Compositions and methods for the modulation of beta chain-mediated immunity
|
|
JP2024540054A
(ja)
|
2021-11-03 |
2024-10-31 |
ヤンセン バイオテツク，インコーポレーテツド |
癌を治療する方法及びｂｃｍａ×ｃｄ３二重特異性抗体の有効性を向上させる方法
|
|
EP4433506A1
(en)
|
2021-11-16 |
2024-09-25 |
Genentech, Inc. |
Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab
|
|
US20250034559A1
(en)
|
2021-11-17 |
2025-01-30 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
IL312968A
(en)
|
2021-11-22 |
2024-07-01 |
Janssen Biotech Inc |
Compositions comprising enhanced multispecific binding agents for an immune response
|
|
CN118284809A
(zh)
|
2021-11-25 |
2024-07-02 |
豪夫迈·罗氏有限公司 |
少量抗体副产物的定量
|
|
US20230183360A1
(en)
|
2021-12-09 |
2023-06-15 |
Janssen Biotech, Inc. |
Use of Amivantamab to Treat Colorectal Cancer
|
|
AR127887A1
(es)
|
2021-12-10 |
2024-03-06 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y plap
|
|
WO2023122723A1
(en)
|
2021-12-23 |
2023-06-29 |
The Broad Institute, Inc. |
Panels and methods for diagnosing and treating lung cancer
|
|
IL314068A
(en)
|
2022-01-24 |
2024-09-01 |
Novimmune Sa |
Preparations and methods for selective activation of cytokine signaling pathways
|
|
US20230241211A1
(en)
|
2022-01-28 |
2023-08-03 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
|
|
WO2023144306A1
(en)
|
2022-01-28 |
2023-08-03 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
|
|
TW202342057A
(zh)
|
2022-02-07 |
2023-11-01 |
美商健生生物科技公司 |
用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法
|
|
CN118574855A
(zh)
|
2022-02-07 |
2024-08-30 |
江苏恒瑞医药股份有限公司 |
特异性结合psma和cd3的抗原结合分子及其医药用途
|
|
WO2023150778A1
(en)
|
2022-02-07 |
2023-08-10 |
Visterra, Inc. |
Anti-idiotype antibody molecules and uses thereof
|
|
AU2023217152A1
(en)
|
2022-02-11 |
2024-08-15 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Immunoconjugate and use thereof
|
|
AU2023232992A1
(en)
|
2022-03-07 |
2024-08-15 |
Novimmune Sa |
Cd28 bispecific antibodies for targeted t cell activation
|
|
US12122850B2
(en)
|
2022-03-14 |
2024-10-22 |
LamKap Bio gamma AG |
Bispecific GPC3xCD28 and GPC3xCD3 antibodies and their combination for targeted killing of GPC3 positive malignant cells
|
|
CN118660910A
(zh)
|
2022-03-14 |
2024-09-17 |
江苏恒瑞医药股份有限公司 |
特异性结合gprc5d和cd3的抗原结合分子及其医药用途
|
|
WO2023174521A1
(en)
|
2022-03-15 |
2023-09-21 |
Genmab A/S |
Binding agents binding to epcam and cd137
|
|
JP2025512785A
(ja)
|
2022-03-23 |
2025-04-22 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
抗ｃｄ２０／抗ｃｄ３二重特異性抗体及び化学療法の併用処置
|
|
EP4499683A1
(en)
|
2022-03-29 |
2025-02-05 |
NGM Biopharmaceuticals, Inc. |
Ilt3 and cd3 binding agents and methods of use thereof
|
|
KR20250004776A
(ko)
|
2022-04-13 |
2025-01-08 |
에프. 호프만-라 로슈 아게 |
항-cd20/항-cd3 이중특이성 항체의 약학 조성물 및 사용 방법
|
|
US20250304689A1
(en)
|
2022-04-13 |
2025-10-02 |
Genmab A/S |
Bispecific antibodies against cd3 and cd20
|
|
CN119421890A
(zh)
|
2022-04-19 |
2025-02-11 |
豪夫迈·罗氏有限公司 |
改进的生产细胞
|
|
CN119072493A
(zh)
|
2022-04-26 |
2024-12-03 |
诺华股份有限公司 |
靶向il-13和il-18的多特异性抗体
|
|
US20250325643A1
(en)
|
2022-05-12 |
2025-10-23 |
Genmab A/S |
Binding agents capable of binding to cd27 in combination therapy
|
|
WO2023218046A1
(en)
|
2022-05-12 |
2023-11-16 |
Genmab A/S |
Binding agents capable of binding to cd27 in combination therapy
|
|
US20250295809A1
(en)
|
2022-05-13 |
2025-09-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
JP2025517572A
(ja)
|
2022-06-03 |
2025-06-05 |
エフ． ホフマン－ラ ロシュ アーゲー |
改良された産生細胞
|
|
KR20250027562A
(ko)
|
2022-06-23 |
2025-02-26 |
지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 |
Dll3 및 cd3에 특이적으로 결합하는 항원 결합 분자 및 이의 의약적 용도
|
|
EP4547715A1
(en)
|
2022-06-30 |
2025-05-07 |
Janssen Biotech, Inc. |
Use of anti-egfr/anti-met antibody to treat gastric or esophageal cancer
|
|
JP2025528068A
(ja)
|
2022-08-03 |
2025-08-26 |
ボイジャー セラピューティクス インコーポレイテッド |
血液脳関門を通過させるための組成物及び方法
|
|
CN119546645A
(zh)
|
2022-08-05 |
2025-02-28 |
江苏恒瑞医药股份有限公司 |
特异性结合gucy2c和cd3的抗原结合分子及其医药用途
|
|
EP4587470A1
(en)
|
2022-09-15 |
2025-07-23 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
|
TW202423969A
(zh)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及蛋白酶體抑制劑之組合療法
|
|
TW202423970A
(zh)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及ｃｄ３８抗體之組合療法
|
|
TW202430211A
(zh)
|
2022-10-10 |
2024-08-01 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及ｉｍｉｄ之組合療法
|
|
EP4602371A1
(en)
|
2022-10-12 |
2025-08-20 |
F. Hoffmann-La Roche AG |
Method for classifying cells
|
|
WO2024084052A1
(en)
|
2022-10-21 |
2024-04-25 |
Novimmune Sa |
Pd-l1xcd28 bispecific antibodies for immune checkpoint-dependent t cell activation
|
|
WO2024089551A1
(en)
|
2022-10-25 |
2024-05-02 |
Janssen Biotech, Inc. |
Msln and cd3 binding agents and methods of use thereof
|
|
EP4612177A1
(en)
|
2022-10-31 |
2025-09-10 |
Genmab A/S |
Cd38 antibodies and uses thereof
|
|
CN120051491A
(zh)
|
2022-11-01 |
2025-05-27 |
上海齐鲁制药研究中心有限公司 |
一种针对磷脂酰肌醇蛋白聚糖3的双特异性抗体及其应用
|
|
AU2023375177A1
(en)
|
2022-11-02 |
2025-06-19 |
Janssen Biotech, Inc. |
Methods of treating cancers
|
|
IL319999A
(en)
|
2022-11-02 |
2025-06-01 |
Genmab As |
Bispecific antibodies against CD3 and CD20 - for the treatment of Richter syndrome
|
|
WO2024100170A1
(en)
|
2022-11-11 |
2024-05-16 |
F. Hoffmann-La Roche Ag |
Antibodies binding to hla-a*02/foxp3
|
|
JP2025537782A
(ja)
|
2022-11-15 |
2025-11-20 |
エフ． ホフマン－ラ ロシュ アーゲー |
活性化可能なエフェクタードメインを有する組換え結合タンパク質
|
|
CN120187748A
(zh)
|
2022-11-15 |
2025-06-20 |
豪夫迈·罗氏有限公司 |
抗原结合分子
|
|
TW202421667A
(zh)
|
2022-11-29 |
2024-06-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
Ｃｌｄｎ１８．２／４－１ｂｂ結合蛋白及其醫藥用途
|
|
AR131635A1
(es)
|
2023-01-20 |
2025-04-16 |
Hoffmann La Roche |
Inmunoconjugados
|
|
CN120569410A
(zh)
|
2023-01-25 |
2025-08-29 |
豪夫迈·罗氏有限公司 |
与csf1r和cd3结合的抗体
|
|
TW202436339A
(zh)
|
2023-01-31 |
2024-09-16 |
瑞士商赫孚孟拉羅股份公司 |
治療選自非小細胞肺癌或三陰性乳癌的癌症之用途
|
|
WO2024163009A1
(en)
|
2023-01-31 |
2024-08-08 |
Genentech, Inc. |
Methods and compositions for treating urothelial bladder cancer
|
|
WO2024168061A2
(en)
|
2023-02-07 |
2024-08-15 |
Ayan Therapeutics Inc. |
Antibody molecules binding to sars-cov-2
|
|
EP4662239A1
(en)
|
2023-02-09 |
2025-12-17 |
Janssen Biotech, Inc. |
Anti-v beta 17/anti-cd123 bispecific antibodies
|
|
WO2024175031A1
(zh)
|
2023-02-21 |
2024-08-29 |
江苏恒瑞医药股份有限公司 |
Il-36r结合蛋白及其医药用途
|
|
EP4676519A1
(en)
|
2023-03-06 |
2026-01-14 |
F. Hoffmann-La Roche AG |
Combination therapy of an anti-egfrviii/anti-cd3 antibody and an tumor-targeted 4-1bb agonist
|
|
EP4680639A1
(en)
|
2023-03-13 |
2026-01-21 |
Janssen Biotech, Inc. |
Combination therapies with bi-specific anti-egfr/c-met antibodies and anti-pd-1 antibodies
|
|
CN120835901A
(zh)
|
2023-03-13 |
2025-10-24 |
豪夫迈·罗氏有限公司 |
采用pd1-lag3双特异性抗体和hla-g t细胞双特异性抗体的组合疗法
|
|
CN120917044A
(zh)
|
2023-04-03 |
2025-11-07 |
豪夫迈·罗氏有限公司 |
激动性拆分型抗体
|
|
WO2024208777A1
(en)
|
2023-04-03 |
2024-10-10 |
F. Hoffmann-La Roche Ag |
All-in-one agonistic antibodies
|
|
TW202506178A
(zh)
|
2023-04-05 |
2025-02-16 |
丹麥商珍美寶股份有限公司 |
包含與ｃｄ３０和ｃｄ３結合之抗體之醫藥組成物
|
|
CN121175072A
(zh)
|
2023-04-11 |
2025-12-19 |
浙江博锐生物制药有限公司 |
抗ror1抗体及其药物偶联物
|
|
KR20250169618A
(ko)
|
2023-04-13 |
2025-12-03 |
젠맵 에이/에스 |
Cd3 및 cd20에 대한 이중특이적 항체를 사용하여 림프종을 치료하는 방법
|
|
CN121127493A
(zh)
|
2023-05-08 |
2025-12-12 |
豪夫迈·罗氏有限公司 |
靶向干扰素 α 融合蛋白及使用方法
|
|
TW202509071A
(zh)
|
2023-05-12 |
2025-03-01 |
丹麥商珍美寶股份有限公司 |
能夠與ｏｘ４０結合之抗體、其變異體及其用途
|
|
TW202509065A
(zh)
|
2023-05-16 |
2025-03-01 |
瑞士商赫孚孟拉羅股份公司 |
經ｐｄ－１調節之ｉｌ－２免疫結合物及其用途
|
|
CA3228195A1
(en)
|
2023-05-23 |
2025-06-30 |
Janssen Biotech, Inc. |
Methods for treatment of non-small cell lung cancer (nsclc)
|
|
CN119143869A
(zh)
|
2023-06-16 |
2024-12-17 |
复旦大学 |
乙肝病毒表面抗体及其应用
|
|
WO2024263904A1
(en)
|
2023-06-23 |
2024-12-26 |
Genentech, Inc. |
Methods for treatment of liver cancer
|
|
WO2024263195A1
(en)
|
2023-06-23 |
2024-12-26 |
Genentech, Inc. |
Methods for treatment of liver cancer
|
|
AR133071A1
(es)
|
2023-06-30 |
2025-08-20 |
Genmab As |
ANTICUERPOS QUE SE UNEN A LA PROTEÍNA DE ACTIVACIÓN DE FIBROBLASTOS a Y AL RECEPTOR DE MUERTE 4
|
|
WO2025021838A1
(en)
|
2023-07-26 |
2025-01-30 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3
|
|
AR133412A1
(es)
|
2023-07-30 |
2025-09-24 |
Janssen Biotech Inc |
Moléculas que se unen a la calreticulina mutante y usos de estas
|
|
US20250066510A1
(en)
|
2023-08-07 |
2025-02-27 |
Janssen Biotech, Inc. |
Gucy2c antibodies and uses thereof
|
|
US20250136688A1
(en)
|
2023-08-07 |
2025-05-01 |
Janssen Biotech, Inc. |
Stabilized cd3 antigen binding agents and methods of use thereof
|
|
WO2025032508A1
(en)
|
2023-08-07 |
2025-02-13 |
Janssen Biotech, Inc. |
Enpp3 and cd3 binding agents and methods of use thereof
|
|
AU2024323186A1
(en)
|
2023-08-09 |
2026-01-15 |
F. Hoffmann-La Roche Ag |
Mono and multispecific anti-trem2 antibodies, methods and uses thereof
|
|
WO2025032071A1
(en)
|
2023-08-09 |
2025-02-13 |
F. Hoffmann-La Roche Ag |
Mono and multispecific anti-trem2 antibodies, methods and uses thereof
|
|
WO2025036892A1
(en)
|
2023-08-14 |
2025-02-20 |
Morphosys Ag |
Cycat halfbody molecules comprising sterically occluding moieties
|
|
WO2025042742A1
(en)
|
2023-08-18 |
2025-02-27 |
Bristol-Myers Squibb Company |
Compositions comprising antibodies that bind bcma and cd3 and methods of treatment
|
|
WO2025052273A1
(en)
|
2023-09-05 |
2025-03-13 |
Janssen Biotech, Inc. |
Methods of treating non-small cell lung cancer
|
|
US20250075000A1
(en)
|
2023-09-06 |
2025-03-06 |
Novimmune Sa |
Combination therapy with a cea x cd28 bispecific antibody and blocking anti-pd-1 antibodies for enhanced in vivo anti-tumor activity
|
|
WO2025059162A1
(en)
|
2023-09-11 |
2025-03-20 |
Dana-Farber Cancer Institute, Inc. |
Car-engager containing il-2 variants to enhance the functionality of car t cells
|
|
WO2025056180A1
(en)
|
2023-09-15 |
2025-03-20 |
BioNTech SE |
Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
|
|
WO2025079020A1
(en)
|
2023-10-12 |
2025-04-17 |
Janssen Biotech, Inc. |
First line treatment in egfr exon 20 insertion-mutated advanced non-small cell lung cancer
|
|
WO2025082777A1
(en)
|
2023-10-17 |
2025-04-24 |
Morphosys Ag |
Dual-targeting of muc16 and mesothelin co-expressing tumor cells by functional complementation of cycat® halfbody molecules
|
|
WO2025085610A1
(en)
|
2023-10-18 |
2025-04-24 |
Janssen Biotech, Inc. |
Combination treatment of prostate cancers with two bispecific antibodies
|
|
TW202535406A
(zh)
|
2023-10-30 |
2025-09-16 |
美商壯生和壯生企業創新公司 |
用於治療肺癌之a2a受體拮抗劑
|
|
TW202540189A
(zh)
|
2023-11-30 |
2025-10-16 |
德商生物新技術公司 |
在組合療法中能夠結合ｏｘ４０之抗體
|
|
WO2025122634A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
TW202535947A
(zh)
|
2023-12-08 |
2025-09-16 |
美商健生生物科技公司 |
ＣＤ３３抗體、ＣＤ３３／Ｖδ２多特異性抗體及其用途
|
|
WO2025125386A1
(en)
|
2023-12-14 |
2025-06-19 |
F. Hoffmann-La Roche Ag |
Antibodies that bind to folr1 and methods of use
|
|
WO2025151018A1
(ko)
*
|
2024-01-12 |
2025-07-17 |
주식회사 노벨티노빌리티 |
C-kit 및 vegf에 특이적으로 결합하는 이중특이적 항체 및 이의 용도
|
|
WO2025153988A1
(en)
|
2024-01-16 |
2025-07-24 |
Janssen Biotech, Inc. |
Use of amivantamab to treat colorectal cancer
|
|
WO2025158277A1
(en)
|
2024-01-22 |
2025-07-31 |
Janssen Biotech, Inc. |
Use of amivantamab to treat head and neck cancer
|
|
WO2025181189A1
(en)
|
2024-03-01 |
2025-09-04 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3
|
|
WO2025191459A1
(en)
|
2024-03-11 |
2025-09-18 |
Janssen Biotech, Inc. |
Use of bispecific anti-egfr/c-met antibodies to treat solid tumors
|
|
WO2025202147A1
(en)
|
2024-03-27 |
2025-10-02 |
F. Hoffmann-La Roche Ag |
Interleukin-7 immunoconjugates
|
|
WO2025221728A2
(en)
|
2024-04-15 |
2025-10-23 |
Janssen Biotech, Inc. |
Ltbr binding molecules and uses thereof
|
|
WO2025219504A1
(en)
|
2024-04-19 |
2025-10-23 |
F. Hoffmann-La Roche Ag |
Treatment of ophthalmologic diseases
|
|
WO2025226541A2
(en)
|
2024-04-26 |
2025-10-30 |
Janssen Biotech, Inc. |
Klk2xcd3 antibody and an anti-cancer agent for treating prostate cancer
|
|
WO2025231408A2
(en)
|
2024-05-03 |
2025-11-06 |
Janssen Biotech, Inc. |
Methods for treating multiple myeloma with car-t cells and bispecific antibodies
|
|
WO2025233825A1
(en)
|
2024-05-06 |
2025-11-13 |
Janssen Pharmaceutica Nv |
Enrichment of cells expressing a bird linker
|
|
WO2025237931A1
(en)
|
2024-05-15 |
2025-11-20 |
F. Hoffmann-La Roche Ag |
Recombinant binding proteins with conditionally activatable t cell and nk cell recruiting effector domains
|
|
US20250361317A1
(en)
|
2024-05-24 |
2025-11-27 |
Janssen Biotech, Inc. |
Bispecific antibody targeting emr2 (cd312) and the t-cell receptor trbv19
|
|
WO2026003224A2
(en)
|
2024-06-26 |
2026-01-02 |
Iomx Therapeutics Ag |
Bispecific antigen binding proteins (abp) targeting immune checkpoint molecules and both leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2; combinations and uses thereof
|
|
WO2026011013A1
(en)
|
2024-07-02 |
2026-01-08 |
Epibiologics, Inc. |
Binding agents and uses thereof
|
